|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
12670 High Bluff Dr, San Diego, CA 92130, US
|
|
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome.
The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital.
For more information, visit www.ocelotbio.com.
|
Ocelot Bio Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Ocelot Bio email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Ocelot Bio customer service number in your country click here to find.
Katherine Vega Stultz is the CEO of Ocelot Bio. To contact Katherine Vega Stultz email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.